Search research articles
Contact Us
Filters
Showing results (51-60 of 73) with videos related to
Page
of 8
Sort By:
The New England Journal of Medicine
|
November 20, 2014
Genetic basis for clinical response to CTLA-4 blockade in melanoma
Alexandra Snyder, Vladimir Makarov, Taha Merghoub, et al.
Plos Medicine
|
May 30, 2017
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis
Alexandra Snyder, Tavi Nathanson, Samuel A Funt, et al.
JCO Precision Oncology
|
September 11, 2020
Radiogenomics Analysis of Intratumor Heterogeneity in a Patient With High-Grade Serous Ovarian Cancer
Britta Weigelt, Hebert Alberto Vargas, Pier Selenica, et al.
Cell
|
April 8, 2017
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B Chiappinelli, Pamela L Strissel, Alexis Desrichard, et al.
Cell
|
April 12, 2016
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B Chiappinelli, Pamela L Strissel, Alexis Desrichard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2018
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
Min Yuen Teo, Kenneth Seier, Irina Ostrovnaya, et al.
Cell
|
August 29, 2015
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B Chiappinelli, Pamela L Strissel, Alexis Desrichard, et al.
Nature Communications
|
April 12, 2022
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma
Jeppe Sejerø Holm, Samuel A Funt, Annie Borch, et al.
Science (New York, N.Y.)
|
March 14, 2015
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, et al.
Nature Medicine
|
July 10, 2023
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
Martin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 73) with videos related to
Sort By:
Page
of 8
The New England Journal of Medicine
|
November 20, 2014
Genetic basis for clinical response to CTLA-4 blockade in melanoma
Alexandra Snyder, Vladimir Makarov, Taha Merghoub, et al.
Plos Medicine
|
May 30, 2017
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis
Alexandra Snyder, Tavi Nathanson, Samuel A Funt, et al.
JCO Precision Oncology
|
September 11, 2020
Radiogenomics Analysis of Intratumor Heterogeneity in a Patient With High-Grade Serous Ovarian Cancer
Britta Weigelt, Hebert Alberto Vargas, Pier Selenica, et al.
Cell
|
April 8, 2017
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B Chiappinelli, Pamela L Strissel, Alexis Desrichard, et al.
Cell
|
April 12, 2016
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B Chiappinelli, Pamela L Strissel, Alexis Desrichard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2018
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
Min Yuen Teo, Kenneth Seier, Irina Ostrovnaya, et al.
Cell
|
August 29, 2015
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B Chiappinelli, Pamela L Strissel, Alexis Desrichard, et al.
Nature Communications
|
April 12, 2022
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma
Jeppe Sejerø Holm, Samuel A Funt, Annie Borch, et al.
Science (New York, N.Y.)
|
March 14, 2015
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, et al.
Nature Medicine
|
July 10, 2023
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
Martin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, et al.
Page
of 8